JNJ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Based on the data provided, Johnson & Johnson does not present a compelling buy opportunity for a beginner investor with a long-term strategy at this moment. While the company has strong financials and positive analyst sentiment, the lack of strong trading signals, insider selling, cautious congress trading activity, and ongoing legal risks suggest a more cautious approach is warranted. Holding or waiting for a better entry point is recommended.
The technical indicators are mixed. While the moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the MACD is negatively expanding (-0.652), and RSI is neutral (52.396). The stock is trading near its pivot level (243.859), with resistance at 246.751 and support at 240.968. This suggests limited immediate upside potential.
Strong Q4 2025 financial performance with revenue up 9.08% YoY, net income up 49.11% YoY, and EPS up 48.23% YoY.
Positive analyst sentiment with multiple price target upgrades and optimistic views on new product cycles in biopharma and MedTech.
Recent clinical trial success with pasritamig and docetaxel showing significant PSA reduction in prostate cancer patients.
Insider selling has increased by 159.20% over the last month, signaling potential caution from company insiders.
Congress trading data shows 4 sale transactions with no purchases, indicating a cautious stance from influential figures.
Legal risks persist, including the talc MDL case and a recent lawsuit related to Tylenol use during pregnancy.
The MACD is negatively expanding, and the stock is trading near its pivot level, suggesting limited short-term upside.
In Q4 2025, Johnson & Johnson reported strong financial growth: revenue increased by 9.08% YoY to $24.56B, net income rose by 49.11% YoY to $5.12B, and EPS grew by 48.23% YoY to $2.09. However, gross margin declined slightly by -0.95% YoY to 67.79%.
Analyst sentiment is generally positive, with multiple firms raising price targets and maintaining Buy or Outperform ratings. RBC Capital raised its target to $255, Morgan Stanley to $262, and Scotiabank to $265, citing strong new product cycles and robust financials. However, some analysts, like BofA and Stifel, remain neutral, citing legal risks and premium valuation concerns.
